| 臺大學術典藏 |
2020-04-10T12:16:14Z |
Gastric perforation presenting as empyema in a patient with pancreatic cancer on bevacizumab treatment
|
Tien Y.-W.; Cheng A.-L.; Liang P.-C.; YU-YUN SHAO; Lin Z.-Z. |
| 臺大學術典藏 |
2020-04-10T12:16:13Z |
Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma
|
YU-YUN SHAO; Lin Z.-Z.; Hsu C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:16:12Z |
Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma
|
YU-YUN SHAO; Lin Z.-Z.; Hsu C.; Lee K.-D.; Hsiao C.-H.; Lu Y.-S.; Huang C.-C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:16:12Z |
High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy
|
YU-YUN SHAO; Lin Z.-Z.; Chen T.-J.; Hsu C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:16:12Z |
Impact of baseline hepatitis B viral DNA levels on survival of patients with advanced hepatocellular carcinoma
|
YU-YUN SHAO; Chen P.-J.; Lin Z.-Z.; Huang C.-C.; Ding Y.-H.; Lee Y.-H.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:16:11Z |
Diabetes mellitus is associated with increased mortality in patients receiving curative therapy for hepatocellular carcinoma
|
Shau W.-Y.; YU-YUN SHAO; Yeh Y.-C.; Lin Z.-Z.; Kuo R.; Hsu C.-H.; Hsu C.; Cheng A.-L.; Lai M.-S. |
| 臺大學術典藏 |
2020-04-10T12:16:11Z |
Survival of patients with small cell lung carcinoma in Taiwan
|
Kuo Y.-H.; Lin Z.-Z.; Yang Y.-Y.; YU-YUN SHAO; Shau W.-Y.; Kuo R.N.C.; Yang J.C.-H.; Lai M.-S. |
| 臺大學術典藏 |
2020-04-10T12:16:10Z |
Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems
|
YU-YUN SHAO; Lu L.-C.; Lin Z.-Z.; Hsu C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:16:10Z |
Survival following surgery with or without adjuvant chemotherapy for stage I-IIIA non-small cell lung cancer: An East Asian population-based study
|
Lin Z.-Z.; Shau W.-Y.; YU-YUN SHAO; Yang Y.-Y.; Kuo R.N.-C.; Yang J.C.-H.; Laie M.-S. |
| 臺大學術典藏 |
2020-04-10T12:16:09Z |
Hospital volume of percutaneous radiofrequency ablation is closely associated with treatment outcomes for patients with hepatocellular carcinoma
|
Kuo R.N.C.; Lin Z.-Z.; Yeh Y.-C.; Shau W.-Y.; Hsu C.-H.; Cheng A.-L.; Lai M.-S.; Lu L.-C.; YU-YUN SHAO |
| 臺大學術典藏 |
2020-04-10T12:16:09Z |
Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer
|
YU-YUN SHAO; Shau W.-Y.; Lin Z.-Z.; Chen H.-M.; Kuo R.; Yang J.C.-H.; Lai M.-S. |
| 臺大學術典藏 |
2020-04-10T12:16:08Z |
Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size
|
Lin Z.-Z.; Shau W.-Y.; Hsu C.; YU-YUN SHAO; Yeh Y.-C.; Kuo R.N.-C.; Hsu C.-H.; Yang J.C.-H.; Cheng A.-L.; Lai M.-S. |
| 臺大學術典藏 |
2020-04-10T12:16:07Z |
Type 2 diabetes mellitus is associated with increased mortality in chinese patients receiving curative surgery for colon cancer
|
Chen K.-H.;Yu-Yun Shao;Lin Z.-Z.;Yeh Y.-C.;Wen-Yi S.;Kuo R.N.;Chen H.-M.;Lai C.-L.;Yeh K.-H.;Cheng A.-L.;Lai M.-S.; Chen K.-H.; YU-YUN SHAO; Lin Z.-Z.; Yeh Y.-C.; Wen-Yi S.; Kuo R.N.; Chen H.-M.; Lai C.-L.; Yeh K.-H.; Cheng A.-L.; Lai M.-S. |
| 臺大學術典藏 |
2020-04-10T12:16:04Z |
Young patients with colorectal cancer have increased risk of second primary cancers
|
Liang Y.-H.;Yu-Yun Shao;Chen H.-M.;Lai C.-L.;Lin Z.-Z.;Kuo R.N.;Cheng A.-L.;Yeh K.-H.;Lai M.-S.; Liang Y.-H.; YU-YUN SHAO; Chen H.-M.; Lai C.-L.; Lin Z.-Z.; Kuo R.N.; Cheng A.-L.; Yeh K.-H.; Lai M.-S. |
| 臺大學術典藏 |
2020-04-10T12:16:04Z |
Comparative effectiveness of first-line platinum-based chemotherapy regimens for advanced lung squamous cell carcinoma
|
Liao B.-C.;Yu-Yun Shao;Chen H.-M.;Shau W.-Y.;Lin Z.-Z.;Kuo R.N.;Lai C.-L.;Chen K.-H.;Cheng A.-L.;Yang J.C.-H.;Lai M.-S.; Liao B.-C.; YU-YUN SHAO; Chen H.-M.; Shau W.-Y.; Lin Z.-Z.; Kuo R.N.; Lai C.-L.; Chen K.-H.; Cheng A.-L.; Yang J.C.-H.; Lai M.-S. |
| 臺大學術典藏 |
2020-04-10T12:16:03Z |
The prognostic impact of type 2 diabetes mellitus on early cervical cancer in Asia
|
Kuo H.-Y.;Lin Z.-Z.;Kuo R.;Shau W.-Y.;Lai C.-L.;Yang Y.-Y.;Yu-Yun Shao;Hsu C.;Cheng W.-F.;Cheng A.-L.;Yang J.C.H.;Lai M.-S.; Kuo H.-Y.; Lin Z.-Z.; Kuo R.; Shau W.-Y.; Lai C.-L.; Yang Y.-Y.; YU-YUN SHAO; Hsu C.; Cheng W.-F.; Cheng A.-L.; Yang J.C.H.; Lai M.-S. |
| 臺大學術典藏 |
2020-04-10T12:16:02Z |
Statin Use Is Associated With Improved Prognosis of Colorectal Cancer in Taiwan
|
Yeh Y.-C.; Lai C.-L.; Lin Z.-Z.; Cheng A.-L.; Lai M.-S.; Yu-Yun Shao;Hsu C.-H.;Yeh K.-H.;Chen H.-M.;Yeh Y.-C.;Lai C.-L.;Lin Z.-Z.;Cheng A.-L.;Lai M.-S.; YU-YUN SHAO; Hsu C.-H.; Yeh K.-H.; Chen H.-M. |
| 臺大學術典藏 |
2020-04-10T12:16:00Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma (HCC): biomarker exploration
|
YU-YUN SHAO; Chen B.-B.; Lin Z.-Z.; Hsu C.-H.; Wang M.-J.; Cheng A.-L.; Hsu C. |
| 臺大學術典藏 |
2020-04-10T12:15:59Z |
Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)
|
Chen Y.-C.; Ohishi N.; O’Neil B.; Schwartz L.; Smith-Jones P.M.; Ohtomo T.; Tanaka T.; Morikawa H.; Maki Y.; Frenette C.; Lin Z.-Z.; YU-YUN SHAO; Wan P.; Ma J.; Lyashchenko S.K.; Gansukh B.; Pandit-Taskar N.; Ruan S.; Beylergil V.; O’Donoghue J.; Abou-Alfa G.K.;Yen C.-J.;Hsu C.-H.;O’Donoghue J.;Beylergil V.;Ruan S.;Pandit-Taskar N.;Gansukh B.;Lyashchenko S.K.;Ma J.;Wan P.;Yu-Yun Shao;Lin Z.-Z.;Frenette C.;O’Neil B.;Schwartz L.;Smith-Jones P.M.;Ohtomo T.;Tanaka T.;Morikawa H.;Maki Y.;Ohishi N.;Chen Y.-C.;Agajanov T.;Boisserie F.;Di Laurenzio L.;Lee R.;Larson S.M.;Cheng A.-L.;Carrasquilo J.A.; Abou-Alfa G.K.; Yen C.-J.; Hsu C.-H.; Agajanov T.; Boisserie F.; Di Laurenzio L.; Lee R.; Larson S.M.; Cheng A.-L.; Carrasquilo J.A. |
| 臺大學術典藏 |
2020-04-10T12:15:58Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
Yu-Yun Shao;Chen B.-B.;Ou D.-L.;Lin Z.-Z.;Hsu C.-H.;Wang M.-J.;Cheng A.-L.;Hsu C.; YU-YUN SHAO; Chen B.-B.; Ou D.-L.; Lin Z.-Z.; Hsu C.-H.; Wang M.-J.; Cheng A.-L.; Hsu C. |
| 臺大學術典藏 |
2020-04-10T12:15:55Z |
Considerations of heterogeneity in clinical trials for hepatocellular carcinoma
|
Liu T.-H.;Yu-Yun Shao;Lu L.-C.;Shen Y.-C.;Hsu C.;Lin Z.-Z.;Hsu C.-H.;Cheng A.-L.; Liu T.-H.; YU-YUN SHAO; Lu L.-C.; Shen Y.-C.; Hsu C.; Lin Z.-Z.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:15:53Z |
Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma
|
Yu-Yun Shao;Liu T.-H.;Hsu C.;Lu L.-C.;Shen Y.-C.;Lin Z.-Z.;Cheng A.-L.;Hsu C.-H.; YU-YUN SHAO; Liu T.-H.; Hsu C.; Lu L.-C.; Shen Y.-C.; Lin Z.-Z.; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2020-04-09T09:39:09Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
Shao, Y. Y.; Chen, B. B.; Ou, D. L.; Lin, Z. Z.; Hsu, C. H.; Wang, M. J.; Cheng, A. L.; Hsu, C. |
| 臺大學術典藏 |
2020-03-30T08:50:53Z |
Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib
|
Shih J.-Y.; JIN-SHING CHEN; Lin Z.-Z.; Lin C.-C.; Yang J.C.H.; Yu C.-J.; Yao Z.-H.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Shih J.-Y.;Jin-Shing Chen;Lin Z.-Z.;Lin C.-C.;Yang J.C.H.;Yu C.-J.; Yao Z.-H.; Liao W.-Y.; Ho C.-C.; Chen K.-Y. |
| 臺大學術典藏 |
2020-03-30T08:50:44Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Yu C.-J.; Yang J.C.-H.; Shih J.-Y.; Lin Z.-Z.; Lee J.-H.; Chen K.-Y.; Yang C.-Y.; Hsu C.-L.; Ho C.-C.; Lin Y.-T.;Jin-Shing Chen;Liao W.-Y.;Ho C.-C.;Hsu C.-L.;Yang C.-Y.;Chen K.-Y.;Lee J.-H.;Lin Z.-Z.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; Lin Y.-T.; JIN-SHING CHEN; Liao W.-Y. |
